Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-848d4c4894-xfwgj Total loading time: 0 Render date: 2024-06-15T10:56:16.792Z Has data issue: false hasContentIssue false

Case 9: - The one that came out of nowhere

Published online by Cambridge University Press:  03 April 2024

By
Hassaan Gomaa
Edited by
Nevena V. Radonjić ,
Thomas L. Schwartz  and
Stephen M. Stahl
Nevena V. Radonjić
Affiliation:
State University of New York Upstate Medical University
Thomas L. Schwartz
Affiliation:
State University of New York Upstate Medical University
Stephen M. Stahl
Affiliation:
University of California, San Diego
Get access

Summary

What is the most common atypical antipsychotic associated with CD?

Keywords

tardive dyskinesiacovert dyskinesiaaripiprazoleantipsychoticsaripiprazole (Abilify)methylphenidate (Ritalin)clonazepam (Klonopin)zolpidem (Ambien)risperidone (Risperdal)haloperidol (Haldol)duloxetine (Cymbalta)mirtazapine (Remeron)valbenazine (Ingrezza)deutetrabenazine (Austedo)
Type
Chapter
Information
Case Studies: Stahl's Essential Psychopharmacology , pp. 149 - 166
Publisher: Cambridge University Press
Print publication year: 2024

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5, 5th edn. Arlington, VA: American Psychiatric Publishing, Inc., 2013Google Scholar
Braude, WM, Barnes, TR. Late-onset akathisia – an indicant of covert dyskinesia: two case reports. Am J Psychiatry 1983; 140:611–12Google ScholarPubMed
Burris, KD, Molski, TF, Xu, C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002; 302:381–9CrossRefGoogle ScholarPubMed
Chang, S, Lin, Y, Pan, Y. Covert dyskinesia associated with aripiprazole: a case report. Taiwanese Journal of Psychiatry 2019; 33:172–3Google Scholar
Fernandez, HH, Factor, SA, Hauser, RA, et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study. Neurology 2017; 88:2003–10CrossRefGoogle ScholarPubMed
Fernandez, HH, Stamler, D, Davis, MD, et al. Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia. J Neurol Neurosurg Psychiatry 2019; 90:1317–23Google ScholarPubMed
Gardos, G, Cole, JO, Tarsy, D. Withdrawal syndromes associated with antipsychotic drugs. Am J Psychiatry 1978; 135:1321–4Google ScholarPubMed
Gomaa, H, Mahgoub, Y, Francis, A. Covert dyskinesia with aripiprazole: tip of the iceberg? A case report and literature review. J Clin Psychopharmacol 2021; 41:67–70CrossRefGoogle ScholarPubMed
Guy, W. ECDEU Assessment Manual for Psychopharmacology, revised edn. Rockville, MD: US Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs, 1976Google Scholar
Moseley, CN, Simpson-Khanna, HA, Catalano, G, et al. Covert dyskinesia associated with aripiprazole: a case report and review of the literature. Clin Neuropharmacol 2013; 36:128–30CrossRefGoogle ScholarPubMed
Patra, S. Tardive dyskinesia and covert dyskinesia with aripiprazole: a case series. Curr Drug Saf 2016; 11:102–3CrossRefGoogle ScholarPubMed
Schooler, NR, Kane, JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982; 39:486–7Google ScholarPubMed
Solmi, M, Pigato, G, Kane, JM, et al. Clinical risk factors for the development of tardive dyskinesia. J Neurol Sci 2018; 389:21–7CrossRefGoogle ScholarPubMed
Stahl, SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications, 5. Cambridge: Cambridge University Press, 2021CrossRefGoogle Scholar
Touma, KTB, Scarff, JR. Valbenazine and deutetrabenazine for tardive dyskinesia. Innov Clin Neurosci 2018; 15:13–16Google ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×